Next Science Limited Stock Today
| NXSCF Stock | USD 0.06 0.02 28.75% |
PerformanceSoft
| Odds Of DistressLow
|
Next Science is trading at 0.057 as of the 26th of December 2025. This is a 28.75 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.057. Next Science has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 26th of November 2025 and ending today, the 26th of December 2025. Click here to learn more.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. The company has 214.79 M outstanding shares. More on Next Science Limited
Moving against Next Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Next Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Next Science Limited [NXSCF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 112.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Next Science's market, we take the total number of its shares issued and multiply it by Next Science's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Next Science Limited classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 214.79 M outstanding shares.
Next Science Limited has accumulated about 11.06 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05.
Check Next Science Probability Of Bankruptcy
Ownership AllocationNext Science Limited maintains a total of 214.79 Million outstanding shares. Next Science Limited holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Next Ownership Details
Next Science Limited Risk Profiles
| Mean Deviation | 4.65 | |||
| Semi Deviation | 8.15 | |||
| Standard Deviation | 15.15 | |||
| Variance | 229.62 |
Next Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Next Science without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Next Science Corporate Management
| Judith MBA | CEO MD | Profile | |
| Michael Morello | VP Sales | Profile | |
| Jacqueline CA | Chief Officer | Profile | |
| Matthew Myntti | Founder CTO | Profile | |
| Jon Swanson | Chief Officer | Profile | |
| AGIA BA | Company Sec | Profile |
Other Information on Investing in Next Pink Sheet
Next Science financial ratios help investors to determine whether Next Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Next with respect to the benefits of owning Next Science security.